Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours.

Aditya BagrodiaAnna SavelyevaJohn T LafinRyan W SpeirGregory T ChesnutAnne Lindsay FrazierSolomon L WolduVitaly Margulis Matthew Jonathan MurrayJames F AmatrudaYair Lotan

Published in: BJU international (2020)

A miRNA-based approach may potentially select patients with Stage I NSGCT for correct treatment in a cost-effective manner. Identification of residual teratoma-only remains an issue. Prospective studies are necessary to validate these findings.

Keyphrases

germ cell
type diabetes
metabolic syndrome
adipose tissue
replacement therapy
bioinformatics analysis